ArticleBioMedicine2026
Chinese herbal medicine treatment and the association with long-term major adverse cardiac events in patients with chronic kidney disease: A propensity-score matched cohort study.
Article in BioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) represents the leading cause of mortality among individuals with chronic kidney disease (CKD). While Chinese herbal medicine (CHM) is commonly used by CKD patients in Taiwan, the impact of CHM use on cardiovascular outcomes in this population remains insufficiently understood. Aims: This study aimed to evaluate the association between CHM use and the long-term risk of major adverse cardiac events (MACEs) in patients with CKD. Methods: Data were obtained from the Taiwan National Health Insurance Research Database to identify patients aged over 20 years with newly diagnosed CKD. A 1:1 propensity score matching was performed based on age, sex, comorbidities, medication use, and CHM exposure, resulting in 6351 matched pairs. Participants were followed from 2000 to 2017 to assess the incidence of MACEs, including heart failure (HF), myocardial infarction (MI), ischemic stroke (IS), cardiovascular death, and all-cause mortality. Results: The CHM group comprised 56.4 % females with a mean age of 49.4 ± 15.3 years. After matching, CHM use was associated with a statistically significant reduction of 23 %-31 % in the adjusted hazard ratios for various cardiovascular outcomes and all-cause mortality (P < 0.001). The most commonly prescribed CHM formula and single herb were Ji-Sheng-Shen-Qi-Wan (JSSQW) and Danshen ( Conclusions: The use of CHM as an adjunct therapy in CKD patients was associated with a significantly lower risk of MACEs and all-cause mortality. These findings support the potential of CHM in cardiovascular risk mitigation among CKD patients and highlight the need for future clinical and ethnopharmacological investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.